Table 1 The main characteristic of the included RCTs
Included trials | Study type | Group | Patients | Follow-up period (months) | Age (years, LP-PRP/HA) | Gender (male/female, N) | OA grades | Outcome measurements | Funding | Trial registration |
|---|---|---|---|---|---|---|---|---|---|---|
Cerza et al., 2012 (Italy) [19] | RCT | LP-PRP HA | 60 60 | 1, 3, 6 | 66.5 ± 11.3 66.2 ± 10.6 | 25/35 28/32 | Kellgren–Lawrence classification 1–3 | WOMAC | Not mentioned | Not mentioned |
Sánchez et al., 2012 (Spain) [18] | RCT | PRGF HA | 79 74 | 6 | 60.5 ± 7.9 58.9 ± 8.2 | NA | Ahlbäck Grades 1–3 | WOMAC, adverse effects | Not mentioned | Not mentioned |
Say et al., 2012 (Turkey) [16] | RCT | LP-PRP HA | 45 45 | 3, 6 | 55.2 ± 7.8 56.2 ± 5.1 | 5/40 6/39 | Kellgren–Lawrence classification 2–3 | VAS, adverse effects | Not mentioned | Not mentioned |
Vaquerizo et al., 2013 (Spain) [21] | RCT | PRGF HA | 48 48 | 6, 12 | 62.4 ± 6.6 64.8 ± 7.7 | 16/32 22/26 | Kellgren–Lawrence classification 2–4 | WOMAC, adverse effects | From the Departments of Orthopaedic Surgery and Clinical, Príncipe de Asturias University Hospital, Alcalá de Henares; Orthopaedic Surgery Department, Fundación García Cugat, Hospital Quirón Barcelona (R.S.), Barcelona; and BTI Biotechnology Institute ImasD, Vitoria, Spain | EudraCT number 2015-004738-90 |
Montañez-Heredia et al., 2016 (Spain) [17] | RCT | LP-PRP HA | 27 26 | 3, 6 | 66.3 ± 8.3 61.5 ± 8.6 | 12/15 9/17 | Kellgren–Lawrence classification 1–3 | Adverse effects | Not mentioned | Not mentioned |
Cole et al., 2017 (USA) [26] | RCT | LP-PRP HA | 49 50 | 6, 12 | 55.9 ± 10.4 56.8 ± 10.5 | 28/21 20/30 | Kellgren–Lawrence classification 2–4 | WOMAC, VAS, IKDC | Aesculap/B. Braun, Arthrex, Athletico, Cytori, Medipost, National Institutes of Health, Ossur, Smith & Nephew, Tornier, and Arthrex and Kensey Nash | Not mentioned |
Raeissadat et al., 2017 (Iran) [22] | RCT | PRGF HA | 36 33 | 2, 3, 6 | 57.0 ± 7.18 59.5 ± 7.54 | 7/29 6/27 | Kellgren–Lawrence classification 1–4 | WOMAC, VAS | No funding | Iranian Registry of Clinical Trials (IRCT): IRCT2013121815860N1 |
Louis et al., 2018 (France) [23] | RCT | LP-PRP HA | 24 24 | 1, 3, 6 | 53.2 ± 11.7 48.5 ± 11.5 | 14/10 11/13 | Kellgren–Lawrence classification 1–4 | WOMAC, VAS, adverse effects | No funding | ClinicalTrials.gov: NCT02211521 |
Buendía‐López et al., 2019 (Spain) [25] | RCT | LP-PRP HA | 33 32 | 6, 12 | 56.15 ± 3.0 56.63 ± 2.9 | 16/17 15/17 | Kellgren–Lawrence classification 1–2 | WOMAC, VAS, adverse effects | No funding | NCT02990745 |
Huang et al., 2019 (China) [24] | RCT | LP-PRP HA | 40 40 | 3, 6, 9, 12 | 54.5 ± 1.2 54.8 ± 1.1 | 25/15 19/21 | Kellgren–Lawrence classification 1–2 | WOMAC, VAS, adverse effects | Not mentioned | BTI-01-EC/07/ART |
Lin et al., 2019 (Taiwan) [20] | RCT | LP-PRP HA | 31 29 | 1, 2, 6, 12 | 61.17 ± 13.08 62.53 ± 9.9 | 9/22 10/19 | Not mentioned | WOMAC, IKDC, adverse effects | Kaohsiung Veterans General Hospital Research Grant (VGHKS 103-075), and was registered with the Government Research Bulletin in Taiwan | PG10301-0457 |
Xu et al., 2021 (China) [15] | RCT | LP-PRP HA | 30 20 | 1, 6, 12, 24 | 56.9 ± 4.2 57.1 ± 3.4 | 10/20 5/15 | Kellgren–Lawrence classification 2–3 | WOMAC, VAS | National Natural Science Foundation of China ( 51,773,098, 81,670,817, 81,970,772, 21,908,019 and 21,776,044), Natural Science Foundation of Tianjin City of China ( 18JCYBJC28300) and the Fundamental Research Funds for Central Universities (China) | ChiCTR-ONC-17013097 |